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An Ovid search for use of the term “medical
futility” since 1980 returns 7,467 results.
Although this subject has received much
academic attention, there remain significant
gaps in our knowledge about how best to
resolve conflicts with surrogates requesting
treatments that clinicians believe should not
be provided. Most of the existing literature
can be assigned to one of three clinician-
centric categories: 1) descriptions of
common surrogate requests and theoretical
resolution strategies, 2) communication
interventions to prevent disputes, and
3) explorations of how requests for a
potentially inappropriate treatment
make clinicians feel. There have been
comparatively few investigations into how
surrogates experience these disputes outside
of the contentious situations where conflicts
rise to the level of public discourse, as
in the cases of Charlie Gard and
Jahi McMath (1, 2).
In 2015, a policy statement approved by
multiple critical care societies, including the
American Thoracic Society, proposed using
the broader term “potentially inappropriate”
to encompass all situations in which
clinicians believe competing ethical
considerations justify withholding
treatments (3). This statement outlined a
multistep process for responding to
surrogates’ requests for such interventions
in intensive care units (ICUs). In this issue
of AnnalsATS, Bailoor and colleagues
(pp. 738–743) explore the reactions of
uninvolved lay citizens to clinical vignettes
concerning resolution of requests for
potentially inappropriate treatment via this
process (4). A nationwide sample of 1,191
adults reviewed two vignettes in which
clinicians withheld one of two treatments
against the wishes of the patient’s daughter:
chemotherapy in the setting of metastatic
cancer and hemodialysis after a devastating
intracerebral hemorrhage. Half of the
respondents were randomized to receive
“process information.” These respondents
were told that the team obtained a second
opinion from an independent physician,
had the case reviewed by the hospital ethics
committee, and explored whether theDOI: 10.1513/AnnalsATS.201903-254ED
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patient could be transferred to another
institution. The other half of the
respondents did not receive this process
information. The primary outcome was a
four-point Likert scale assessing responses
to the question, “How appropriate do you
find the decisions made by the doctors?”
Two of the study’s findings are
noteworthy. First, acceptance of the decision
to withhold treatment was high. Combining
both vignettes and treatment arms, more
than 77% of the respondents rated
withholding treatment as appropriate. This
demonstrates that a majority of uninvolved
Americans support decisions to withhold
therapies when clinicians believe that
treatment would be of no benefit or that the
risks and harms outweigh the benefits. This
finding is consistent with a 2009 study in
which 82% of actual ICU surrogates agreed
to withhold treatment in a hypothetical
scenario (i.e., not their loved one’s scenario)
when clinicians believed the patient had no
chance of survival (5). Some data support
the intuitive finding that surrogates’
agreement with an initial recommendation
of withholding or withdrawing treatment is
lower when the subject is an actual loved
one. In a study in a pediatric ICU, when
clinicians approached families regarding
withholding or withdrawing life-sustaining
treatment, 51% of families agreed in the first
family meeting with the assessment (6). This
agreement went up with each additional
family meeting (reaching .98% agreement
after multiple meetings).
The second novel finding is the effect of
process transparency on public acceptance
of the decision to withhold treatment.
Acceptance was improved by approximately
10% in both scenarios when the resolution
process used by the treating team was
discussed with transparency. This simple
intervention had a number needed to treat
of 10 to prevent one disagreement—a
success rate better than most standard
pharmacologic interventions (for example,
the number needed to treat to prevent
ischemic stroke with anticoagulation is
25) (7).
Interestingly, the respondents were
asked to address the vignettes not from the
point of view of the surrogate, but as an
uninvolved observer. There are at least two
possible views of how this aspect of the study
design impacts interpretation of these
findings. A purist evaluation would lead to
the conclusion that this study addresses the
general public’s views of these situations.
However, because it was evaluated from a
third-party perspective, it is difficult to
conclude whether such transparency would
have the same effect in bedside disputes
that don’t rise to the level of a national
discussion.
A more interpretive assessment would
view this study as a thought experiment that
removes emotion and personal context from
the respondent. In this view, participants’
responses represent the views of surrogates
at the bedside from a dispassionate
standpoint. Thus, process transparency
appears to be an effective means of
improving surrogates’ acceptance of
disputed recommendations, and should be a
standard part of the resolution process.
The authors acknowledge that studying
a group of third-party individuals is far
removed from trialing interventions with
actual surrogates. But this study seems
to add empiric support for process
transparency at the bedside, a step that 1) is
consistent with current guidelines in the
aforementioned American Thoracic Society
policy statement, 2) is likely to be of low risk
and beneficial to surrogates, and 3) is
without added cost, assuming that a
guideline-based resolution process occurs
regularly.
Perhaps the most surprising aspect of
this study is the fact that the authors felt
compelled to carry it out in the first place.
(And this is not a refutation of its value—
we found this study compelling and
informative.) That we feel the need to
empirically justify open communication
about a systematic medical decision-making
process speaks volumes about the current
state of patient–physician communication
in the United States. Clinicians in the United
States remain responsible for directing
difficult decisions at the extremes of life
at a time when ideas about previously
unassailable concepts, such as the definition
of death, are evolving (8). The steps outlined
in the multisociety policy statement are
meant to ensure that we will do what we
believe is right while also having the
humility to check with colleagues about our
assumptions. This study establishes that one
of the fundamental ways of improving
communication and building trust in
contentious situations is simply to show our
work. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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